Yap Boum II

Yap Boum II


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
AAAbubakari Ahmed
Abubakari Ahmed
AAAceil Al-Khatib
Aceil Al-Khatib
YIYap Boum II
Yap Boum II
Humberto DebatHumberto Debat
Humberto Debat
ADAlonso Gurmendi Dunkelberg
Alonso Gurmendi Dunkelberg
JPJ. Andrew Pruszynski
J. Andrew Pruszynski

4 June 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
MBMarie Roseline Darnycka BELIZAIRE
Marie Roseline Darnycka BELIZAIRE
LILynka Ineza
Lynka Ineza
IFIbrahima Socé Fall
Ibrahima Socé Fall
MOMitoha Ondo
Mitoha Ondo
YIYap Boum II
Yap Boum II

8 February 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ONOlivia Ngou
Olivia Ngou
RNRomaric Nzoumbou-Boko
Romaric Nzoumbou-Boko
PBPascal Bakamba
Pascal Bakamba
YIYap Boum II
Yap Boum II

Verified
Journal Article
Open access
PDF file
Jean-Philippe ChippauxJean-Philippe Chippaux
Jean-Philippe Chippaux
YMYoann Madec
Yoann Madec
PAPierre Amta
Pierre Amta
RNRodrigue Ntone
Rodrigue Ntone
GNGaëlle Noël
Gaëlle Noël
FTFabien Taieb
Fabien Taieb
Snakes responsible for bites are rarely identified, resulting in a loss of information about snakebites from venomous species whose venom effects are poorly understood. A prospective clinical study including patients bitten by a snake was conducted in Cameroon between 2019 and 2021 to evaluate the efficacy and tolerability of a marketed polyvalent antivenom. Clinical presentation during the first 3 days of hospitalization was recorded following a standardized protocol. This ancillary study aimed to assess the frequency of bites by the different species encountered in Cameroon and to describe the symptoms of bites by formally identified species. Of the 447 patients included in the study, 159 (35.6%) brought the snake that caused the bite that was identified by a specialist. Out of these, 8 specimens could not be identified due to poor condition, 19 were non-venomous species, and 95 belonged to Echis romani—formerly E. ocellatus—species. The remaining 37 specimens included 2 Atheris squamigera, 12 Atractaspis spp., 2 Bitis arietans, 11 Causus maculatus, 1 Dendroaspis jamesoni, 1 Naja haje, 1 N. katiensis, 5 N. melanoleuca complex, and 2 N. nigricollis. Symptoms, severity of envenomation, and post-treatment course are described. Symptoms and severity of bites are consistent with cases described in the literature, but some specific features are highlighted.

1 April 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
Boris Tchakounte YounguiBoris Tchakounte Youngui
Boris Tchakounte Youngui
EEEmilienne Epée
Emilienne Epée
TDTatiana Djikeussi
Tatiana Djikeussi
JFJoseph Fokam
Joseph Fokam
MGMichelle M. Gill
Michelle M. Gill
: During the 33rd Africa Cup of Nations (AFCON) football tournament in Cameroon, organizers and health authorities required a negative SARS-CoV-2 test result <48 hours before entry and provided free SARS-CoV-2 testing and vaccination at stadium and fan zone entrances. We describe the outcomes and implementation of mandatory SARS-CoV-2 testing at fan zones during AFCON. All consenting fan zones attendees were administered an electronic questionnaire capturing exposure factors, COVID-19-like symptoms, and COVID-19 vaccination status, before being tested for SARS-CoV-2 using an antigen rapid diagnostic test (Ag-RDT). Participants testing positive were sampled for confirmatory real-time SARS-CoV-2 polymerase chain reaction (PCR) and sequencing for variant surveillance. The case detection rate was estimated using PCR-confirmed cases, and the challenges were summarized from staff discussions and project/study documentation. In total, 4,820 fan zone attendees (median [interquartile range] age 30 [24–38], 27.7% females) were tested for SARS-CoV-2, including 1,228 (25.5%) fully vaccinated. Of 4,820 participants, 148 (3.1%) had a positive Ag-RDT result, of whom 67 consented to PCR testing and 19 of 64 (29.7%) were confirmed PCR-positive. The case detection rate was 40.1 (95% CI: 24.2–62.7) per 10,000 attendees. The Omicron variant (B.1.1.529) was found in all 11 samples successfully sequenced. The implementation of mandatory SARS-CoV-2 Ag-RDT at fan zone entrances was challenged by high attendance volume just prior to matches, lobbying of economic stakeholders, and inconsistent quality assurance when using test kits. Despite the challenges encountered, implementing mandatory SARS-CoV-2 Ag-RDT at fan zones, was a unique opportunity for SARS-CoV-2 case identification and genomic surveillance.

22 March 2024 in Toxins
Verified
Journal Article
Open access
PDF file
DBDavid Benhammou
David Benhammou
Jean-Philippe ChippauxJean-Philippe Chippaux
Jean-Philippe Chippaux
RNRodrigue Ntone
Rodrigue Ntone
YMYoann Madec
Yoann Madec
PAPierre Amta
Pierre Amta
FTFabien Taieb
Fabien Taieb
Snakebite envenomation (SBE) is a public health issue in sub-Saharan countries. Antivenom is the only etiological treatment. Excellent tolerance is essential in managing SBE successfully. This study aimed to evaluate tolerance of InoserpTM PAN-AFRICA (IPA). It was conducted on fourteen sites across Cameroon. IPA was administered intravenously and repeated at the same dose every two hours if needed. Early and late tolerance was assessed by the onset of clinical signs within two hours and at a visit two weeks or more after the first IPA administration, respectively. Over 20 months, 447 patients presenting with a snakebite were included. One dose of IPA was administered to 361 patients and repeated at least once in 106 patients. No significant difference was shown between the proportion of adverse events in patients who received IPA (266/361, 73.7%) and those who did not (69/85, 81.2%) (p = 0.95). Adverse reactions, probably attributable to IPA, were identified in four (1.1%) patients, including one severe (angioedema) and three mild. All these reactions resolved favorably. None of the serious adverse events observed in twelve patients were attributed to IPA. No signs of late intolerance were observed in 302 patients. Tolerance appears to be satisfactory. The availability of effective and well-tolerated antivenoms would reduce the duration of treatment and prevent most disabilities and/or deaths.